Financial Analysis: Nabriva Therapeutics (NASDAQ:NBRV) versus Acerus Pharmaceuticals (NASDAQ:ASPCF)

Nabriva Therapeutics (NASDAQ:NBRV) and Acerus Pharmaceuticals (OTCMKTS:ASPCF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Volatility & Risk

Nabriva Therapeutics has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Insider and Institutional Ownership

3.2% of Nabriva Therapeutics shares are held by institutional investors. 3.3% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Nabriva Therapeutics and Acerus Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nabriva Therapeutics $9.66 million 156.54 -$114.78 million ($1.63) -1.18
Acerus Pharmaceuticals $7.38 million 1.77 -$18.79 million N/A N/A

Acerus Pharmaceuticals has lower revenue, but higher earnings than Nabriva Therapeutics.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nabriva Therapeutics and Acerus Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nabriva Therapeutics 0 1 5 0 2.83
Acerus Pharmaceuticals 0 0 0 0 N/A

Nabriva Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 284.62%. Given Nabriva Therapeutics’ higher possible upside, equities research analysts plainly believe Nabriva Therapeutics is more favorable than Acerus Pharmaceuticals.


This table compares Nabriva Therapeutics and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nabriva Therapeutics -910.45% -171.36% -93.30%
Acerus Pharmaceuticals -219.97% -674.63% -115.96%


Nabriva Therapeutics beats Acerus Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.